Precision oncology program for advanced cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Precision Oncology Program (POP) is an observational collaboration aimed at generating insights into the individual tumor biology of patients with advanced malignancies. By utilizing innovative biotechnologies and comparing patient profiles against specific databases, the program seeks to inform clinical decision-making regarding potential treatment benefits. The study includes routine genetic testing and advanced imaging mass cytometry to capture tumor heterogeneity and predict therapy responses. This approach aims to integrate precision oncology into clinical practice effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent
* In the case of deceased persons: signed general consent
* All patients with the diagnosis of a solid tumour including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma, etc
* ECOG-performance status 0-2, if applicable
* Willing and able to understand all project related procedures, including transfer of coded (i.e. pseudonymised) or anonymized clinical data to external partners (e.g. Roche), if applicable

Exclusion Criteria:

* Patients with the diagnosis of blood cancer.

Where it's running

• University Hospital Zürich (Universitätsspital Zürich)
  Zurich, Switzerland Recruiting

Study contacts

• Study coordinator: Andreas Wicki, Professor
• Email: andreas.wicki@usz.ch
• Phone: +41 44 255 38 99

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term outcomes after vacuum-induced tamponade for postpartum hemorrhage

  This study will look at women who had postpartum hemorrhage treated with vacuum-induced tamponade at a Zurich hospital to see how they fared over time, including future pregnancies and fertility.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07885072

• Add-on Sildenafil Before Exercise in PAH to See if Max Workload Improves

  This study tests whether taking 20 mg sildenafil right before exercise helps people with pulmonary arterial hypertension perform more work during cardiopulmonary testing.

  Recruiting Phase 2/3 University of Zurich · Zurich, Canton of Zurich · NCT07824674

• Fatigue Investigation Using Digital Outcomes

  This study tests whether digital monitoring with a smartphone app and wearables can track fatigue in people with MS or long COVID, compared with healthy volunteers.

  Recruiting at 6 sites University of Zurich · Basel, Basel and 5 other locations · NCT07783074

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

  This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777367

• Daily adjustment of radiation dose in MRI-guided SBRT for abdominal and pelvic tumors

  This trial tests whether adjusting the radiation dose in real-time during MRI-guided SBRT improves targeting for abdominal or pelvic tumors.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07687147

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.